Private company
Audentes Therapeutics, Inc.
American biological products company based in San Francisco. Summary from the record
Last updated Oct 21, 2026.
Overview
- IndustryBiological Products, (No Diagnostic Substances)2
- HeadquartersSan Francisco, United States2
- Legal formCorporation2
- LEI549300PZYT0QC9UNJF132
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 52406622
Corporate structure
Audentes Therapeutics, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
- Audentes Therapeutics, Inc. San Francisco, California, United States
- Taysha Gene Therapies, Inc. Stake · Dallas, Texas
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.
Leadership
Who has led Audentes Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
- PresidentNatalie C. Holles May 8, 2018 to Jan 15, 20203
- Chief financial officerThomas P. Soloway Jul 19, 2016 to Jan 15, 20204
- Chief operating officerNatalie C. Holles Jul 19, 2016 to Jan 15, 20205
Board members and other officers (17)
- SVP, Chief Commercial OfficerEric Mosbrooker Jan 4, 2019 to Jan 15, 20206
- SVP, Chief Medical OfficerEdward R. Conner Jul 17, 2019 to Jan 15, 20207
- SVP, HR & Corp. AffairsDavid Nagler Jul 19, 2016 to Jun 22, 20188
- Senior Vice President, R & DJohn T. Gray Jul 19, 2016 to Oct 2, 20189
- SVP, Regulatory AffairsMary Newman Jul 19, 2016 to Nov 16, 201810
- Senior VP & Chief Med OfficerSuyash Prasad Jul 19, 2016 to Jun 7, 201911
- Board memberJennifer Jarrett Jun 13, 2017 to Jan 15, 202012
- Board memberJonathan Silverstein Jul 19, 2016 to Aug 25, 201613
- Board memberKush Parmar Jul 19, 2016 to Jun 8, 201814
- Board memberLouis G. Lange Jul 19, 2016 to Jan 15, 202015
- Board memberSamuel D. Isaly Jul 19, 2016 to Jul 19, 201616
- Board memberScott W. Morrison Jul 19, 2016 to Jan 15, 202017
- Board memberStephen P. Squinto Jul 19, 2016 to Oct 10, 201718
- Board memberThomas J. Schuetz Jul 19, 2016 to Jan 15, 202019
- Board memberThomas Woiwode Jul 19, 2016 to Aug 25, 201620
- Board memberJulie Smith Dec 13, 2016 to Jan 15, 202021
- General counselMark A. Meltz Apr 1, 2019 to Jan 15, 202022
Stakes it holds
Audentes Therapeutics, Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).
- Taysha Gene Therapies, Inc.SC 13D Oct 31, 202223
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3SEC EDGARNatalie C. Holles, President
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARMary Newman, SVP, Regulatory Affairs
- 11
- 12SEC EDGARJennifer Jarrett, Board member
- 13SEC EDGARJonathan Silverstein, Board member
- 14SEC EDGARKush Parmar, Board member
- 15SEC EDGARLouis G. Lange, Board member
- 16SEC EDGARSamuel D. Isaly, Board member
- 17SEC EDGARScott W. Morrison, Board member
- 18SEC EDGARStephen P. Squinto, Board member
- 19SEC EDGARThomas J. Schuetz, Board member
- 20SEC EDGARThomas Woiwode, Board member
- 21SEC EDGARJulie Smith, Board member
- 22SEC EDGARMark A. Meltz, General counsel
- 23